HiFiBiO Raises $75 Million for Clinical Trials and Drug Discovery
June 14, 2021 at 05:28 AM EDT
HiFiBiO, a US-China biotech, closed a $75 million Series D financing to support clinical trials of its two leading antibody therapies for oncology. HiFiBiO uses its proprietary single-B-cell functional antibody discovery platform, CelliGO™, to discover candidates. In addition to developing its own drugs, the company has formed several strategic discovery partnerships with pharmas and biotechs. The D round was led by new investor Mirae Asset, a global company. HiFiBiO is headquartered in Cambridge , Mass. with operations in Shanghai , Hangzhou , Paris and Hong Kong . More details.... Share this with colleagues: // //
